Cancer
Microbiome company Enterome plans $108m raise to fund Phase II cancer trials
The latest fundraise will close in 2024, with plans for one Phase II trial to start by mid-2024.
Clinigen clears out cancer therapies in line with latest growth strategy
SN Bioscience’s nano-cancer therapy wins orphan drug designation
Immunotherapy insights: Oncolytic viruses struggle to find a spot in a crowded field
Unmet needs remain in treatment of triple negative breast cancer
Lisata shares pipeline update of anticancer lead candidate drug
